Moderna stands to earn $300M for quick vaccine approval, up to $6.6B for extra doses: filing
Moderna’s coronavirus vaccine deal with the U.S., announced last week with a $ 1.525 billion price tag, would be worth far more if all options are exercised—and if the mRNA biotech meets an aggressive timeline for the shot’s arrival. The company stands to gain up to a whopping $ 8.125 billion, according to a Moderna… Read More »